Inovio Pharmaceuticals Inc
NASDAQ:INO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.97
13.88
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Inovio Pharmaceuticals Inc
Total Liabilities & Equity
Inovio Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Inovio Pharmaceuticals Inc
NASDAQ:INO
|
Total Liabilities & Equity
$107.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-2%
|
||
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$143.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$54.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
||
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$90.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$22.2B
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
25%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$37.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
Inovio Pharmaceuticals Inc
Glance View
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.
See Also
What is Inovio Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
107.1m
USD
Based on the financial report for Sep 30, 2024, Inovio Pharmaceuticals Inc's Total Liabilities & Equity amounts to 107.1m USD.
What is Inovio Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-2%
Over the last year, the Total Liabilities & Equity growth was -45%. The average annual Total Liabilities & Equity growth rates for Inovio Pharmaceuticals Inc have been -42% over the past three years , -7% over the past five years , and -2% over the past ten years .